Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal

Samra Turajlic(Royal Marsden NHS Foundation Trust), Hang Xu(The Francis Crick Institute), Kevin Litchfield(The Francis Crick Institute), Andrew Rowan(The Francis Crick Institute), Tim Chambers(The Francis Crick Institute), José I. López(University of the Basque Country), David Nicol(Royal Marsden NHS Foundation Trust), Tim O’Brien(Guy's and St Thomas' NHS Foundation Trust), James Larkin(Royal Marsden NHS Foundation Trust), Stuart Horswell(The Francis Crick Institute), Mark Stares(Royal Marsden NHS Foundation Trust), Lewis Au(Royal Marsden NHS Foundation Trust), Mariam Jamal‐Hanjani(Cancer Research UK), Ben Challacombe(Guy's and St Thomas' NHS Foundation Trust), Ashish Chandra(Guy's and St Thomas' NHS Foundation Trust), Steve Hazell(Royal Marsden NHS Foundation Trust), Claudia Eichler-Jonsson(The Francis Crick Institute), Aspasia Soultati(Guy's and St Thomas' NHS Foundation Trust), Simon Chowdhury(Guy's and St Thomas' NHS Foundation Trust), Sarah Rudman(Guy's and St Thomas' NHS Foundation Trust), Joanna Lynch(Royal Marsden NHS Foundation Trust), Archana Fernando(Guy's and St Thomas' NHS Foundation Trust), Gordon Stamp(The Francis Crick Institute), Emma Nye(The Francis Crick Institute), Faiz Jabbar(The Francis Crick Institute), Lavinia Spain(Royal Marsden NHS Foundation Trust), Sharanpreet Lall(Guy's and St Thomas' NHS Foundation Trust), Rosa Guarch(Complejo Hospitalario de Navarra), Mary Falzon(University College Hospital), Ian Proctor(University College Hospital), Lisa Pickering(Royal Marsden NHS Foundation Trust), Martin Gore(Royal Marsden NHS Foundation Trust), Thomas B.K. Watkins(The Francis Crick Institute), Sophia Ward(The Francis Crick Institute), Aengus Stewart(University of the Basque Country), Renzo G. DiNatale(Memorial Sloan Kettering Cancer Center), Maria F. Becerra(Memorial Sloan Kettering Cancer Center), Ed Reznik(Memorial Sloan Kettering Cancer Center), James J. Hsieh(Washington University in St. Louis), Todd Richmond(Madison Group (United States)), George F. Mayhew(Madison Group (United States)), Samantha M. Hill(Ventana Research Corporation (United States)), Catherine D. McNally(Ventana Research Corporation (United States)), Carol Jones(Ventana Research Corporation (United States)), Heidi Rosenbaum(Madison Group (United States)), Stacey Stanislaw(Ventana Research Corporation (United States)), Daniel L. Burgess(Madison Group (United States)), Nelson R. Alexander(Ventana Research Corporation (United States)), Charles Swanton(The Francis Crick Institute)
Cited by 870Open Access
Full Text

Abstract

Clear-cell renal cell carcinoma (ccRCC) exhibits a broad range of metastatic phenotypes that have not been systematically studied to date. Here, we analyzed 575 primary and 335 metastatic biopsies across 100 patients with metastatic ccRCC, including two cases sampledat post-mortem. Metastatic competence was afforded by chromosome complexity, and we identify 9p loss as a highly selected event driving metastasis and ccRCC-related mortality (p = 0.0014). Distinct patterns of metastatic dissemination were observed, including rapid progression to multiple tissue sites seeded by primary tumors of monoclonal structure. By contrast, we observed attenuated progression in cases characterized by high primary tumor heterogeneity, with metastatic competence acquired gradually and initial progression to solitary metastasis. Finally, we observed early divergence of primitive ancestral clones and protracted latency of up to two decades as a feature of pancreatic metastases.


Related Papers

No related papers found

Powered by citation graph analysis